The Experts below are selected from a list of 7683 Experts worldwide ranked by ideXlab platform
Arunee Sabchareon - One of the best experts on this subject based on the ideXlab platform.
-
a three year clinical study on immunogenicity safety and booster response of purified chick embryo cell Rabies Vaccine administered intramuscularly or intradermally to 12 to 18 month old thai children concomitantly with japanese encephalitis Vaccine
Pediatric Infectious Disease Journal, 2009Co-Authors: Krisana Pengsaa, Arunee Sabchareon, P Attanath, Kriengsak Limkittikul, Churdchoo Ariyasriwatana, Pornthep Chanthavanich, Claudius MalerczykAbstract:After concomitant administration of purified chick embryo cell Rabies Vaccine and Japanese encephalitis Vaccine to toddlers, adequate Rabies and Japanese encephalitis virus neutralizing antibodies concentrations were demonstrated by day 49, 7 days after a booster at 1 year, and in the majorly at 3 years postvaccination. The inclusion of Rabies Vaccine in the expanded program on immunization should be considered in Rabies endemic countries.
-
a new vero cell Rabies Vaccine results of a comparative trial with human diploid cell Rabies Vaccine in children
Clinical Infectious Diseases, 1999Co-Authors: Arunee Sabchareon, Pornthep Chantavanich, Chanathep Pojjaroenanant, P Attanath, Jean Lang, Chukiat Sirivichayakul, Krisana Pengsaa, Valentine Le Mener, Vipa Prarinyanuphab, Sawat NimnualAbstract:We evaluated the immunogenicity and safety of a chromatographically purified Rabies Vaccine (CPRV) compared with human diploid cell Rabies Vaccine (HDCV) after pre-exposure immunizations (both primary and booster). Intramuscular doses of either 0.5 mL of CPRV or 1.0 mL of HDCV were given to 400 schoolchildren on days 0, 7, 28, and 365 (booster). Adequate titers of antibody (> or = 0.15 IU/mL, as defined by the Centers for Disease Control and Prevention) were observed in serum samples from all children 14 days after primary immunization with CPRV and HDCV; the antibodies persisted in all but one child up until 1 year. Fourteen days after the primary immunization series (day 42) and 7 days after booster immunization (day 372), all children had antibody titers of > or = 0.5 IU/mL. Local and systemic reactions after primary and booster immunizations occurred significantly less frequently in the CPRV group. A severe allergic reaction (angioedema) was reported in only one child after booster immunization with HDCV. CPRV has adequate immunogenicity for primary and booster pre-exposure immunizations in children and has a better safety profile than does HDCV.
-
persistence of antibodies in children after intradermal or intramuscular administration of preexposure primary and booster immunizations with purified vero cell Rabies Vaccine
Pediatric Infectious Disease Journal, 1998Co-Authors: Arunee Sabchareon, Pornthep Chantavanich, Chanathep Pojjaroenanant, Vipa Prarinyanupharb, Vanvarothai Singhasivanon, Wantana Buppodom, P Attanath, Sataporn Pasuralertsakul, Jean LangAbstract:Background. The use of intradermal (id) injections of purified Vero cell Rabies Vaccine (PVRV) for preexposure prophylaxis has not been well-established. We studied the safety and immunogenicity of id and intramuscular (im) PVRV injections for primary and booster preexposure immunizations. Methods. One of two Rabies preexposure PVRV regimens comprising three doses of either 0.1 ml id or 0.5 ml im administered during 28 days was assigned at random to 190 school children. One booster dose was given 1 year later either id or im, according to their initial randomization group. Serologic results were available from 155 (82%) children at 1 year after primary immunization and 118 (62%) children at 2 years after booster. Results. Although children vaccinated id had significantly lower Rabies-neutralizing antibody titers after primary immunization as well as after booster than children vaccinated im (P < 0.001 for all time points), there were no significant differences in the percentages of children with adequate titers (≥0.15 IU/ml) between the id and im groups after both primary and booster immunizations. Mild local reactions were more frequent after id vaccination. Mild or moderate systemic reactions were infrequent and similar after id and im vaccinations. Fever and headache were reported by ≤6%. The reactions after booster were not different from those of post-primary immunization. Conclusions. Purified Vero cell Rabies Vaccine appears to be safe and immunogenic for primary and booster preexposure immunizations. An id PVRV preexposure regimen should be useful especially for Rabies-endemic countries with low per capita income.
P Attanath - One of the best experts on this subject based on the ideXlab platform.
-
a three year clinical study on immunogenicity safety and booster response of purified chick embryo cell Rabies Vaccine administered intramuscularly or intradermally to 12 to 18 month old thai children concomitantly with japanese encephalitis Vaccine
Pediatric Infectious Disease Journal, 2009Co-Authors: Krisana Pengsaa, Arunee Sabchareon, P Attanath, Kriengsak Limkittikul, Churdchoo Ariyasriwatana, Pornthep Chanthavanich, Claudius MalerczykAbstract:After concomitant administration of purified chick embryo cell Rabies Vaccine and Japanese encephalitis Vaccine to toddlers, adequate Rabies and Japanese encephalitis virus neutralizing antibodies concentrations were demonstrated by day 49, 7 days after a booster at 1 year, and in the majorly at 3 years postvaccination. The inclusion of Rabies Vaccine in the expanded program on immunization should be considered in Rabies endemic countries.
-
a new vero cell Rabies Vaccine results of a comparative trial with human diploid cell Rabies Vaccine in children
Clinical Infectious Diseases, 1999Co-Authors: Arunee Sabchareon, Pornthep Chantavanich, Chanathep Pojjaroenanant, P Attanath, Jean Lang, Chukiat Sirivichayakul, Krisana Pengsaa, Valentine Le Mener, Vipa Prarinyanuphab, Sawat NimnualAbstract:We evaluated the immunogenicity and safety of a chromatographically purified Rabies Vaccine (CPRV) compared with human diploid cell Rabies Vaccine (HDCV) after pre-exposure immunizations (both primary and booster). Intramuscular doses of either 0.5 mL of CPRV or 1.0 mL of HDCV were given to 400 schoolchildren on days 0, 7, 28, and 365 (booster). Adequate titers of antibody (> or = 0.15 IU/mL, as defined by the Centers for Disease Control and Prevention) were observed in serum samples from all children 14 days after primary immunization with CPRV and HDCV; the antibodies persisted in all but one child up until 1 year. Fourteen days after the primary immunization series (day 42) and 7 days after booster immunization (day 372), all children had antibody titers of > or = 0.5 IU/mL. Local and systemic reactions after primary and booster immunizations occurred significantly less frequently in the CPRV group. A severe allergic reaction (angioedema) was reported in only one child after booster immunization with HDCV. CPRV has adequate immunogenicity for primary and booster pre-exposure immunizations in children and has a better safety profile than does HDCV.
-
persistence of antibodies in children after intradermal or intramuscular administration of preexposure primary and booster immunizations with purified vero cell Rabies Vaccine
Pediatric Infectious Disease Journal, 1998Co-Authors: Arunee Sabchareon, Pornthep Chantavanich, Chanathep Pojjaroenanant, Vipa Prarinyanupharb, Vanvarothai Singhasivanon, Wantana Buppodom, P Attanath, Sataporn Pasuralertsakul, Jean LangAbstract:Background. The use of intradermal (id) injections of purified Vero cell Rabies Vaccine (PVRV) for preexposure prophylaxis has not been well-established. We studied the safety and immunogenicity of id and intramuscular (im) PVRV injections for primary and booster preexposure immunizations. Methods. One of two Rabies preexposure PVRV regimens comprising three doses of either 0.1 ml id or 0.5 ml im administered during 28 days was assigned at random to 190 school children. One booster dose was given 1 year later either id or im, according to their initial randomization group. Serologic results were available from 155 (82%) children at 1 year after primary immunization and 118 (62%) children at 2 years after booster. Results. Although children vaccinated id had significantly lower Rabies-neutralizing antibody titers after primary immunization as well as after booster than children vaccinated im (P < 0.001 for all time points), there were no significant differences in the percentages of children with adequate titers (≥0.15 IU/ml) between the id and im groups after both primary and booster immunizations. Mild local reactions were more frequent after id vaccination. Mild or moderate systemic reactions were infrequent and similar after id and im vaccinations. Fever and headache were reported by ≤6%. The reactions after booster were not different from those of post-primary immunization. Conclusions. Purified Vero cell Rabies Vaccine appears to be safe and immunogenic for primary and booster preexposure immunizations. An id PVRV preexposure regimen should be useful especially for Rabies-endemic countries with low per capita income.
Angelika Banzhoff - One of the best experts on this subject based on the ideXlab platform.
-
purified chick embryo cell culture Rabies Vaccine interchangeability with human diploid cell culture Rabies Vaccine and comparison of one versus two dose post exposure booster regimen for previously immunized persons
Vaccine, 2000Co-Authors: David W Dreesen, Uwe Nicolay, Rolan D. Davis, Jean E Chin, Chandra R Gordon, Angelika BanzhoffAbstract:Abstract The equivalence and interchangeability of Purified Chick Embryo Cell Culture Rabies Vaccine (PCECV) to Human Diploid Cell Culture Rabies Vaccine (HDCV) and the immunogenicity of a reduced post-exposure regimen with PCECV was investigated. Statistical analyses revealed no difference ( P ≤0.05) between the geometric mean titers (GMT) on day 49 of subjects that received PCECV or HDCV. In Year 2, subjects were boosted with one or two dose(s) of PCECV. No significant difference ( P ≤0.05) was detected between the GMT of the two groups on days 7 and 365 post-booster. Subjects that received HDCV initially developed an adequate anamnestic response to PCECV. On day 21 post-booster, the GMT of subjects that received two boosters was higher (151.6 IU/ml) than those that received one booster (120.9 IU/ml). However, this difference may not be clinically significant.
Jenny G Low - One of the best experts on this subject based on the ideXlab platform.
-
a phase ii randomized study to determine the safety and immunogenicity of the novel pika Rabies Vaccine containing the pika adjuvant using an accelerated regimen
Vaccine, 2017Co-Authors: Shirin Kalimuddin, Linfa Wang, Limin Wijaya, Yvonne Fu Zi Chan, Abigail W L Wong, Julaihabee A Kassim, Jing Zhao, Zhongkai Shi, Jenny G LowAbstract:Abstract Background Human Rabies infection continues to be potentially fatal despite the availability of post-exposure prophylaxis with Rabies Vaccine. The PIKA Rabies Vaccine adjuvant is a TLR3 agonist and has been shown to be safe and immunogenic in clinical phase I studies. Methods We conducted a phase II, open label, randomized study in healthy adults to assess the safety and immunogenicity of the PIKA Rabies Vaccine under an accelerated regimen. 126 subjects were randomized into two groups: control Vaccine classic regimen (“control-classic”) and PIKA Vaccine accelerated regimen (“PIKA-accelerated”). Subjects were followed up for safety and Rabies virus neutralizing antibodies (RVNA). Results Both the control and PIKA Vaccines were generally well tolerated. 57.6% of subjects in the PIKA Vaccine group, compared with 43.8% of subjects in the control-classic group, achieved the target RVNA titer of ≥0.5 IU/mL by Day 7. All subjects achieved the target RVNA titer by Day 14. The RVNA geometric mean titer at Day 7 was 0.60 IU/ml in the PIKA Vaccine group and 0.39 IU/ml in the control-classic group. At Day 14, the RVNA geometric mean titer was 18.25 IU/ml in the PIKA-accelerated group and 19.24 IU/ml in the control-classic group. The median time taken to reach the target RVNA titer level of ≥0.5 IU/mL was 7.0 days (95% CI: 7.0–42.0 days) in the PIKA-accelerated group and 14.0 days (95% CI: 7.0–42.0 days) in the control-classic group. Conclusion The accelerated regimen using the investigational PIKA Rabies Vaccine was well-tolerated and demonstrated non-inferior immunogenicity compared to the classic regimen using the commercially available Vaccine in healthy adults. Clinical trial registry: The study was registered with clinicaltrials.gov ( NCT02956421 ).
-
an accelerated Rabies Vaccine schedule based on toll like receptor 3 tlr3 agonist pika adjuvant augments Rabies virus specific antibody and t cell response in healthy adult volunteers
Vaccine, 2017Co-Authors: Limin Wijaya, Linfa Wang, Christine Y L Tham, Yvonne Fu Zi Chan, Abigail W L Wong, Antonio Bertoletti, Jenny G LowAbstract:Abstract Background Rabies is a fatal disease where post-exposure prophylaxis (PEP) is crucial in preventing infection. However, deaths even after appropriate PEP, have been reported. The PIKA Rabies Vaccine adjuvant is a TLR3 agonist that activates B and T cells leading to a robust immune response. Methods We conducted a phase I, open label, randomized study in healthy adults to assess the safety and immunogenicity of the PIKA Rabies Vaccine and an accelerated Vaccine regimen. Thirty-seven subjects were randomized into 3 groups: control Vaccine classic regimen, PIKA Vaccine classic regimen and PIKA Vaccine accelerated regimen. Subjects were followed up for safety, Rabies virus neutralizing antibodies (RVNA) and T cell responses. Results Both the control and PIKA Rabies Vaccine were well tolerated. All adverse events (AEs) were mild and self-limiting. Seventy-five percent of subjects in the PIKA accelerated regimen achieved a RVNA titer ⩾0.5 IU/mL on day 7, compared to 53.9% in the PIKA classic regimen (p = 0.411) and 16.7% in control Vaccine classic regimen (p = 0.012). The PIKA Rabies Vaccine elicited multi-specific Rabies CD4 mediated T cell response already detectable ex vivo at day 7 after vaccination and that was maintained at day 42. Conclusion The investigational PIKA Rabies Vaccine was well tolerated and more immunogenic than the commercially available Vaccine in healthy adults. Clinical trial registry: The study was registered with clinicaltrials.gov NCT02657161 .
Haradanahalli S Ravish - One of the best experts on this subject based on the ideXlab platform.
-
safety of purified chick embryo cell Rabies Vaccine administered in previously vaccinated animal handlers working in a biological park
International Journal of Advanced Community Medicine, 2019Co-Authors: H S Anwith, Nitu Kumari, M P Ramya, Haradanahalli S RavishAbstract:Background: Wild animal handlers are at continuous risk of exposure to Rabies. They have to be protected against Rabies by pre-exposure Rabies vaccination and regular booster doses. Methodology: The study was conducted in a biological park in Karnataka during October 2018. Animal handlers working in the various capacities at the park and having taken three primary doses of anti-Rabies Vaccine as pre-exposure prophylaxis were the study subjects. The booster dose of anti- Rabies Vaccine was administered by a team of trained vaccinators. After the vaccination all the subjects were observed for any adverse reactions for thirty minutes; subsequently the subjects were followed up for any adverse drug reactions through telephone for a period of 30 days. Results: The study included 198 subjects with a mean age of 38.1 + 12 years. Only 8 adverse reactions were reported from 8 subjects immediately following vaccination. The adverse reactions were itching 3 (1.5%) & redness 5 (2.5%); which subsided without any complications. None of the subjects developed systemic or delayed adverse reactions. Conclusion: Booster dose Rabies vaccination with purified chick embryo cell Rabies Vaccine is safe in previously vaccinated animal handlers.
-
pre exposure prophylaxis against Rabies in children safety of purified chick embryo cell Rabies Vaccine vaxirab n when administered by intradermal route
Human Vaccines & Immunotherapeutics, 2013Co-Authors: Haradanahalli S RavishAbstract:WHO recommends that children living in highly endemic regions be considered for pre-exposure prophylaxis with Rabies Vaccine, since they will be at continual, frequent or increased risk of exposure to the animal bites.1 The recommendations will come from WHO only after it has been proven by many previous scientific studies among children which have shown that pre-exposure prophylaxis using Purified Chick Embryo Cell Vaccine (PCECV) is safe and well tolerated.2-4 This has been mentioned in the discussion. The authors have not claimed/nor assumed in any part of their manuscript that they are the first to demonstrate the safety of purified chick embryo cell Rabies Vaccine when administered by intradermal route for pre-exposure prophylaxis against Rabies in children.
-
boosting effect of purified chick embryo cell Rabies Vaccine using the intradermal route in persons previously immunized by the intramuscular route or vice versa
The National Medical Journal of India, 2006Co-Authors: M K Sudarshan, Haradanahalli S Ravish, Shampur Narayan Madhusudana, B J Mahendra, D H Narayana, M S Giri, K Muhamuda, G M VenkateshAbstract:BACKGROUND At present, in the event of re-exposure to Rabies, 2 booster doses are recommended for people who have been previously vaccinated with cell culture Rabies Vaccines by the conventional intramuscular route. As the intradermal route of vaccination is likely to be introduced in the future, we investigated the immune response to a cell culture Rabies Vaccine after crossing over from the intramuscular to the intradermal route and vice versa. METHODS Twenty healthy adult volunteers who had received a primary course of Rabies vaccination with purified chick embryo cell Rabies Vaccine by either the intramuscular (n = 10) or intradermal (n = 10) route received booster vaccination with the same Vaccine by the alternative route. The regimen used was 0.1 ml of Vaccine by the intradermal route at two sites (deltoid area) for the intramuscular group, or 1 ml of Vaccine by the intramuscular route (deltoid muscle) to the intradermal group on days 0 and 3. RESULTS There was a 15-fold rise in the Rabies virus neutralizing antibody response both by the intradermal and intramuscular routes of booster vaccination (p < 0.0001). Thus, the change of route of purified chick embryo cell booster vaccination did not alter the anamnestic immune response to the Vaccine. No side-effects were observed after vaccination with either of the routes. CONCLUSION Purified chick embryo cell Vaccine was found to be safe and immunologically efficacious following booster vaccination after cross-over from the intradermal to the intramuscular route and vice versa.
